Presentations and films
2025
Celon Group results - Q3 2025
Celon Group results - H1 2025
Company Results - Q1 2025
mBank Healthcare Days May 8, 2025
Results of the Phase II clinical trial of the PDE10A inhibitor LiD
CPL’36 Unlocking New Possibilities in LiDTreatment – Phase 2 Top-Line Results
2024
The Company's financial results - Q3 2024
The Company's financial results - half-year 2024
Results of the Phase II clinical trial of the PDE10A inhibitor_schizophrenia
Falkieri on its own - transaction with Tang Capital
IQ 2024 Investor Conference Call
Teleconference - 18/06/2024
Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL’36)
2023
Investor Teleconference Y2023
Investor Conference Call 3Q 2023
Investor Teleconference 1H 2023
Investor Conference Call 1Q2023
2022
Investor's teleconference Y2022
Presentation Q3 2022
Investor's teleconference 1Q 2022
2021
Investor's teleconference
Capital Markets Day - 21.04.2021
Transcript >
Watch full CMD webcast >
Corporate deck >
Watch KOL's session >
Watch Corporate session >
Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression
Shareholders of Celon Pharma S.A. On February 16, 2021, they will decide to authorize the Management Board to increase the share capital within the authorized capital by issuing new shares.